Redhill Biopharma Ltd. (RDHL): Price and Financial Metrics

Redhill Biopharma Ltd. (RDHL)

Today's Latest Price: $6.84 USD

0.03 (0.44%)

Updated Jul 2 11:25am

Add RDHL to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

RDHL Stock Summary

  • With a price/sales ratio of 37.56, RedHill Biopharma Ltd has a higher such ratio than 95.42% of stocks in our set.
  • Over the past twelve months, RDHL has reported earnings growth of 96.35%, putting it ahead of 88.79% of US stocks in our set.
  • Revenue growth over the past 12 months for RedHill Biopharma Ltd comes in at 209,600%, a number that bests 99.98% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to RDHL, based on their financial statements, market capitalization, and price volatility, are CRSP, SLGL, EMITF, ZLAB, and CLSD.
  • Visit RDHL's SEC page to see the company's official filings. To visit the company's web site, go to
RDHL Daily Price Range
RDHL 52-Week Price Range

RDHL Stock Price Chart Technical Analysis Charts

RDHL Price/Volume Stats

Current price $6.84 52-week high $9.12
Prev. close $6.81 52-week low $3.26
Day low $6.78 Volume 72,984
Day high $6.92 Avg. volume 361,357
50-day MA $7.06 Dividend yield N/A
200-day MA $6.17 Market Cap 241.25M

Redhill Biopharma Ltd. (RDHL) Company Bio

RedHill Biopharma Ltd. focuses on the development and acquisition of late clinical-stage, proprietary, and orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers in Israel. The company was founded in 2009 and is based in Tel Aviv, Israel.

RDHL Latest News Stream

Event/TimeNews Detail
Loading, please wait...

RDHL Latest Social Stream

Loading social stream, please wait...

View Full RDHL Social Stream

Latest RDHL News From Around the Web

Below are the latest news stories about RedHill Biopharma Ltd that investors may wish to consider to help them evaluate RDHL as an investment opportunity.

RedHill Biopharma to Present at the Sachs Novel Coronavirus Investment Forum

The presentation will be available on the Company's website, on July 7, 2020 for a period of 30 days. Pre-clinical data have demonstrated both anti-inflammatory and anti-viral activities of opaganib, with the potential to reduce lung inflammatory disorders, such as pneumonia, and mitigate pulmonary fibrotic damage.

Yahoo | July 1, 2020

RedHill (RDHL) to Study Opaganib for Severe Coronavirus in UK

RedHill's (RDHL) CTA gets approval in the United Kingdom to start a phase II/III study on opaganib for patients hospitalized with severe COVID-19 infection and pneumonia.

Yahoo | June 30, 2020

RedHill Biopharma to start late-stage study in UK for opaganib for Covid-19

RedHill Biopharma ([[RDHL]] -6.5%) announces that the UK Medicines & Healthcare products Regulatory Agency ((MHRA)) has approved the Company’s clinical trial application to commence a Phase 2/3 study evaluating opaganib in patients hospitalized with severe SARS-CoV-2 infection (the cause of COVID-19) and pneumonia.The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 study will enroll...

Seeking Alpha | June 29, 2020

RedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in the UK

RedHill has also submitted CTA applications for this study in Russia and Italy and plans to expand the study to additional countries. The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 study is set to enroll up to 270 subjects with severe COVID-19 pneumonia requiring hospitalization and treatment with supplemental oxygen.

Yahoo | June 29, 2020

Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

NEW YORK, June 29, 2020 -- Life Sciences Investor Forum today announced that the presentations from the June 25th conference are now available for on-demand viewing at.

Yahoo | June 29, 2020

Read More 'RDHL' Stories Here

RDHL Price Returns

1-mo -4.20%
3-mo 43.70%
6-mo 15.15%
1-year 1.94%
3-year -18.86%
5-year -60.96%
YTD 12.69%
2019 9.37%
2018 7.98%
2017 -50.86%
2016 -18.79%
2015 -3.38%

Continue Researching RDHL

Want to see what other sources are saying about RedHill Biopharma Ltd's financials and stock price? Try the links below:

RedHill Biopharma Ltd (RDHL) Stock Price | Nasdaq
RedHill Biopharma Ltd (RDHL) Stock Quote, History and News - Yahoo Finance
RedHill Biopharma Ltd (RDHL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.9779 seconds.